On March 5, 2024, the FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) decided that the B/Yamagata lineage of influenza viruses will not be included in the formulations for next winter’s flu vaccine.
“In the interest of public health, [the] FDA strongly recommended to influenza vaccine manufacturers the removal of the B/Yamagata lineage virus from seasonal influenza vaccines in the U.S. for the 2024-2025 influenza season,” the FDA